Prognostic value of CD133+CD54+CD44+ circulating tumor cells in colorectal cancer with liver metastasis,Cancer Medicine

当前位置： X-MOL 学术 › Cancer Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Prognostic value of CD133+CD54+CD44+ circulating tumor cells in colorectal cancer with liver metastasis
Cancer Medicine ( IF 2.9 ) Pub Date : 2017-11-03 , DOI: 10.1002/cam4.1241
Chao Fang _{1,

2} , Chuanwen Fan _{1,

2} , Cun Wang ₁ , Qiaorong Huang ₃ , Wentong Meng ₃ , Yongyang Yu ₁ , Lie Yang ₁ , Jiankun Hu ₁ , Yuan Li ₂ , Xianming Mo ₃ , Zongguang Zhou _{1,

2}

Affiliation

In the previous study, we had showed the expression of CD133⁺CD54⁺CD44⁺ cellular subpopulation of circulating tumor cells (CTCs) was significantly associated with liver metastasis of colorectal cancer (CRC). This study aimed to explore whether this subpopulation of CTCs have a prognostic value in CRC patients. Flow cytometry was used to detect the expression of cellular subpopulations of CTCs with CD133, CD54, and CD44 in 152 CRC patients, between December 2013 and October 2014. The impact of clinicopathological factors and the expression of cellular subpopulations of CTCs on overall survival were then analyzed. CRC patients with liver metastases who underwent resection of the primary tumor accompanied by surgical treatment for metastasis had a better survival than other patients (P < 0.001). The liver metastatic CRC patients with high expression of CD133⁺CD54⁺ (P < 0.001), CD133⁻CD54⁺ (P = 0.004), and CD133⁺CD44⁺CD54⁺ (P = 0.003) cellular subpopulations of CTCs had a worse survival than those patients with low expression. Multivariable survival analyses identified carcinoembryonic antigen levels (hazard ratio [HR] = 3.056; 95% confidence interval [CI] = 1.354–6.897; P = 0.007), treatment strategy (HR = 0.212; 95% CI = 0.056–0.808; P = 0.023), and CD133⁺CD44⁺CD54⁺ cellular subpopulation of CTCs (HR = 6.459; 95% CI = 1.461–28.558; P = 0.014) as independent prognostic factors for CRC patients with liver metastasis. CD133⁺CD44⁺CD54⁺ cellular subpopulation of CTCs has a prognostic value in CRC patients with liver metastasis, especially in the survival of CRC patients with liver metastasis who did not undergo surgical treatment for metastasis. Surgical treatment of liver metastasis is important for the treatment of metastatic CRCs. CD133+CD44+CD54+ subpopulation of CTCs has the prognostic value in CRCs and affects the survival of CRCs without surgical treatment of metastases.

中文翻译：

CD133 + CD54 + CD44 +循环肿瘤细胞在大肠癌肝转移中的预后价值

在先前的研究中，我们已经证明了CD133 ⁺ CD54 ⁺ CD44 ⁺的表达循环肿瘤细胞（CTC）的细胞亚群与大肠癌（CRC）的肝转移显着相关。这项研究旨在探讨这种CTC亚群在CRC患者中是否具有预后价值。在2013年12月至2014年10月之间，使用流式细胞仪检测了152例CRC患者中CD133，CD54和CD44的CTC细胞亚群的表达。分析。接受原发肿瘤切除并伴有转移瘤的外科手术治疗的肝转移的CRC患者比其他患者生存率更高（P < 0.001）。高表达CD133的肝转移性CRC患者⁺ CD54 ⁺（P < 0.001），CD133 ^- CD54 ⁺（P = 0.004）和CD133 ⁺ CD44 ⁺ CD54 ⁺（P = 0.003）CTC的细胞亚群的存活率比低表达患者差。多变量生存分析确定了癌胚抗原水平（危险比[HR] = 3.056； 95％置信区间[CI] = 1.354–6.897；P = 0.007），治疗策略（HR = 0.212； 95％CI = 0.056-0.808；P = 0.023）和CD133 ⁺ CD44 ⁺ CD54 ⁺CTCs的细胞亚群（HR = 6.459； 95％CI = 1.461–28.558；P = 0.014）是CRC肝转移患者的独立预后因素。CD133 ⁺ CD44 ⁺ CD54 ⁺ CTC的细胞亚群在患有肝转移的CRC患者中，特别是在未经手术治疗的CRC肝转移患者的生存中具有预后价值。肝转移的外科治疗对于转移性CRC的治疗很重要。CTC的CD133 + CD44 + CD54 +亚群在CRC中具有预后价值，并且在不进行转移瘤手术治疗的情况下影响CRC的生存。

更新日期：2017-12-15

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南